Disease · MONDO_0015597

palmoplantar pustulosis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. palmoplantar pustulosis. Diseases, record MONDO_0015597. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0015597

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: palmoplantar pustulosis; Open Targets
Open Targets ID: MONDO_0015597; Open Targets
Other names: LPP, PPP, localised pustular psoriasis, localized pustular psoriasis, pustulosis of palm and sole, pustulosis palmaris et plantaris; Open Targets
Disease Ontology: DOID:4398; Disease Ontology
NCI Thesaurus: C34888; NCI Thesaurus
Orphanet: ORPHA:163927; Orphanet
Highest stage of its drugs: Phase 3, for 9 of its 17 drugs, from ClinicalTrials.gov; Open Targets

Drugs17

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
APREMILAST	CHEMBL514800	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
GUSELKUMAB	CHEMBL2364648	Antibody	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
BIMEKIZUMAB	CHEMBL4297700	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
BRODALUMAB	CHEMBL1742996	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ETANERCEPT	CHEMBL1201572	Protein	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
IMATINIB	CHEMBL941	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
RISANKIZUMAB	CHEMBL3990029	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
TOFACITINIB	CHEMBL221959	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
USTEKINUMAB	CHEMBL1201835	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
SPESOLIMAB	CHEMBL4297911	Antibody	Phase 2	ClinicalTrials.gov and TTD	4	3	3	Drugs and targets

1 to 10 of 17

See all 17 drugs

Targets27

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
IL12B	Interleukin-12	3	Interleukin-12 inhibitor; Interleukin-23 inhibitor	Phase 3	https://conductscience.org/library/genes/3593	Drugs and targets
IL23A	Interleukin-23	3	Interleukin-23 inhibitor	Phase 3	https://conductscience.org/library/genes/51561	Drugs and targets
TYK2	Janus Kinase (JAK)	3	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase TYK2 negative allosteric modulator	Phase 3	https://conductscience.org/library/genes/7297	Drugs and targets
IL1RAP	IL36 receptor	2	IL36 receptor antagonist	Phase 2	https://conductscience.org/library/genes/3556	Drugs and targets
IL36R	IL36 receptor	2	IL36 receptor antagonist	Phase 2	https://conductscience.org/library/genes/8808	Drugs and targets
JAK1	Janus Kinase (JAK)	2	Janus Kinase (JAK) inhibitor	Phase 3	https://conductscience.org/library/genes/3716	Drugs and targets
JAK2	Janus Kinase (JAK)	2	Janus Kinase (JAK) inhibitor	Phase 3	https://conductscience.org/library/genes/3717	Drugs and targets
JAK3	Janus Kinase (JAK)	2	Janus Kinase (JAK) inhibitor	Phase 3	https://conductscience.org/library/genes/3718	Drugs and targets
ABL1	Bcr/Abl fusion protein	1	Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor	Phase 3	https://conductscience.org/library/genes/25	Drugs and targets
BCR	Bcr/Abl fusion protein	1	Bcr/Abl fusion protein inhibitor	Phase 3	https://conductscience.org/library/genes/613	Drugs and targets

1 to 10 of 27

See all 27 targets

Trials22

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT05174065	Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)	Phase 3	176	2025-04-09	Palmoplantar Pustulosis	APREMILAST	Its record names the disease	ClinicalTrials.gov
NCT02641730	An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis	Phase 3	159	2019-02-21	Palmoplantar Pustulosis	GUSELKUMAB	Its record names the disease	ClinicalTrials.gov
NCT04015518	A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis	Phase 2	152	2022-07-28	Palmoplantar Pustulosis (PPP)	SPESOLIMAB	Its record names the disease	ClinicalTrials.gov
NCT04493424	A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab	Phase 2	108	2024-03-20	Palmoplantar Pustulosis	SPESOLIMAB	Its record names the disease	ClinicalTrials.gov
NCT04057937	A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis	Phase 2	90	2022-01-06	Palmoplantaris Pustulosis	APREMILAST	Its record names the disease	ClinicalTrials.gov
NCT05194839	A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)	Phase 2	79	2023-06-29	Palmoplantar Pustulosis	VIMNERIXIN	Its record names the disease	ClinicalTrials.gov
NCT03135548	Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients	Phase 2	59	2019-11-26	Psoriasis	SPESOLIMAB	Its record names the disease	ClinicalTrials.gov
NCT03633396	A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis	Phase 2	59	2022-05-31	Palmoplantar Pustulosis	IMSIDOLIMAB	Its record names the disease	ClinicalTrials.gov
NCT03988335	A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)	Phase 2	35	2022-03-03	Palmoplantar Pustulosis	VIMNERIXIN	Its record names the disease	ClinicalTrials.gov
NCT01245140	Efficacy of Alitretinoin Treatment in Patients With Pustular Form of Psoriasis	Phase 2	33	2017-04-04	Psoriasis	ALITRETINOIN	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 22

See all 22 trials

Comparisons in its trials6

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Imsidolimab vs Placebo: deaths from any cause	0 of 30	0 of 29	59	NCT03633396	Trial comparisons
Imsidolimab vs Placebo: serious adverse events	0 of 30	1 of 29	59	NCT03633396	Trial comparisons
RIST4721 300 mg vs Placebo: deaths from any cause	0 of 15	0 of 19	34	NCT03988335	Trial comparisons
RIST4721 300 mg vs Placebo: serious adverse events	0 of 15	0 of 19	34	NCT03988335	Trial comparisons
Alitretinoin 30 mg vs Matching Placebo: serious adverse events	1 of 24	0 of 9	33	NCT01245140	Trial comparisons
Etanercept vs Placebo: serious adverse events	0 of 10	0 of 5	15	NCT00353119	Trial comparisons

Papers from its trials8

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
34077577	RESULT	1	PubMed
42543660	DERIVED	1	PubMed
41297955	DERIVED	1	PubMed
38954226	DERIVED	1	PubMed
37731086	DERIVED	1	PubMed
34716902	DERIVED	1	PubMed
31268476	DERIVED	1	PubMed
29417135	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0015597

GET https://conductscience.org/api/diseases/v1/MONDO_0015597/targets?page=2

API reference For AI assistants